IMOJEV
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Jul 11, 2013 → Mar 11, 2014
NCT ID
NCT01900444About IMOJEV
IMOJEV is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01900444. Target conditions include Japanese Encephalitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01900444 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis